Orchestra BioMed Holdings, Inc. recently conducted a clinical study to evaluate the efficacy of Atrioventricular Interval Modulation (AVIM) therapy, also known as BackBeat CNT, in pacemaker-indicated patients with uncontrolled hypertension. The study aimed to compare AVIM therapy with standard right ventricular (RV) pacing in terms of systolic blood pressure and overall cardiac function. The results of this pressure-volume (PV) loop study, conducted at Na Homolce Hospital in Prague under the supervision of Prof. Petr Neuil, M.D. were presented at the Technology and Heart Failure Therapeutics (THT) 2024 Meeting by Prof. Karl-Heinz Kuck, M.D. Medical Director at LANS Cardio Hamburg.
Methodology:The PV loop study included pacemaker-indicated patients who experienced uncontrolled hypertension despite the use of antihypertensive medication. The study involved the delivery of AVIM therapy using both conduction system and standard pacing lead locations. The was to assess the impact of AVIM therapy on systolic blood pressure and overall cardiac function, as measured through pressure-volume loops.
Results:The data from the PV loop study demonstrated significant improvements in hemodynamic parameters in patients receiving AVIM therapy compared to those with standard RV pacing. AVIM therapy exhibited a positive effect on systolic blood pressure, showcasing its potential to address uncontrolled hypertension in pacemaker patients. Additionally, AVIM therapy demonstrated a favorable impact on overall cardiac function, indicating its potential to enhance the quality of life for these individuals.
Implications and Future Directions:The positive outcomes of this study suggest that AVIM therapy holds promise as a potential treatment option for hypertensive pacemaker-indicated patients. By modulating the atrioventricular interval, AVIM therapy can effectively improve systolic blood pressure and overall cardiac function. Future research should aim to further investigate the long-term effects and clinical utility of AVIM therapy in a larger cohort of patients.
Comments